• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    51 Biggest Movers From Yesterday

    2/9/22 4:04:51 AM ET
    $ANGH
    $BATL
    $CYRN
    $EDIT
    Telecommunications Equipment
    Consumer Discretionary
    Oil & Gas Production
    Energy
    Get the next $ANGH alert in real time by email

     

    Also check out this: Apple And 3 Other Stocks Sold By Insiders

    Losers

    • SelectQuote, Inc. (NYSE:SLQT) shares tumbled 47.3% to close at $3.44 on Tuesday after the company swung to a loss in the second quarter. Credit Suisse downgraded SelectQuote from Outperform to Neutral and lowered the price target from $14 to $4.
    • Pulse Biosciences, Inc. (NASDAQ:PLSE) fell 34.4% to close at $7.12. Pulse Biosciences, said on Feb, 5 it received letter from the FDA in which the FDA stated it did not believe co. provided sufficient clinical evidence to support expanded indication for use to expand CellFX System's current labeling.
    • Anghami Inc. (NASDAQ:ANGH) fell 30.9% to close at $13.47. Anghami shares climbed 62% on Monday following its recent listing on NASDAQ.
    • Graham Corporation (NYSE:GHM) fell 24.4% to settle at $8.90 after the company reported worse-than-expected Q3 results and issued FY22 sales guidance below estimates.
    • Eros STX Global Corporation (NYSE:ESGC) fell 22.6% to close at $3.12.
    • Nuvectis Pharma, Inc. (NASDAQ:NVCT) shares dipped 20.5% to close at $6.32 after jumping around 145% on Monday.
    • Karyopharm Therapeutics Inc. (NASDAQ:KPTI) fell 20% to close at $8.19 after reporting Q4 results. Karyopharm said Phase 3 SIENDO study meet primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer.
    • Gelesis Holdings, Inc. (NYSE:GLS) dropped 15.6% to settle at $4.00.
    • GoHealth, Inc. (NASDAQ:GOCO) fell 14.9% to close at $1.95.
    • Battalion Oil Corporation (NYSE:BATL) dipped 14.6% to settle at $14.50.
    • Cyren Ltd. (NASDAQ:CYRN) dropped 14.4% to settle at $0.2038 after the company announced a 1-for-20 reverse split.
    • SES AI Corporation (NYSE:SES) fell 14.3% to close at $6.08.
    • Edgewell Personal Care Company (NYSE:EPC) dropped 13.2% to settle at $37.19 after the company reported worse-than-expected Q2 sales results and updated guidance.
    • Novavax, Inc. (NASDAQ:NVAX) fell 12% to close at $83.45. Novavax 8-K showed modification no. 13 of its project deal no. 1 with Advanced Technology was executed on Feb. 1, 2022.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) fell 11.8% to settle at $106.42.
    • Leafly Holdings, Inc. (NASDAQ:LFLY) dropped 11.2% to close at $6.27. Leafly recently commenced trading on NASDAQ under ticker 'LFLY.'
    • Micro Focus International plc (NYSE:MFGP) shares fell 10.3% to close at $5.47.
    • Editas Medicine, Inc. (NASDAQ:EDIT) shares fell 9.7% to close at $17.44.

    Also check out this: PayPal And 3 Other Stocks Bought By Insiders

    Get the next $ANGH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGH
    $BATL
    $CYRN
    $EDIT

    CompanyDatePrice TargetRatingAnalyst
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Graham Corporation
    $GHM
    1/27/2026$80.00Outperform → Market Perform
    Northland Capital
    GoHealth Inc.
    $GOCO
    11/19/2025Outperform → Mkt Perform
    William Blair
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Graham Corporation
    $GHM
    10/21/2025Outperform → Market Perform
    Noble Capital Markets
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Graham Corporation Reports Third Quarter Fiscal 2026 Results

    Third Quarter Fiscal 2026 Highlights: Revenue increased 21% to $56.7 million Gross profit increased 15% to $13.5 million; Gross profit margin was 23.8% Net income per diluted share increased 79% to $0.25; adjusted net income per diluted share1 increased 72% to $0.31 Adjusted EBITDA1 increased 50% to $6.0 million; Adjusted EBITDA margin1 was 10.7% Orders2 were $71.7 million; Book-to-Bill ratio2 of 1.3x and record backlog2 of $515.6 million Strong balance sheet with no debt, $22.3 million in cash, and access to $43.0 million under its revolving credit facility at quarter end to support growth initiatives Updating and increasing full year fiscal 2026 guidance; Remain on tr

    2/6/26 6:30:00 AM ET
    $GHM
    Industrial Machinery/Components
    Industrials

    Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

    Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA. Key study findings include: 100% procedural success of

    2/5/26 7:00:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Bentsur Ron bought $28,600 worth of shares (5,000 units at $5.72), increasing direct ownership by 0.14% to 3,525,924 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:01:11 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sanchez Juan bought $75,270 worth of shares (13,000 units at $5.79), increasing direct ownership by 20% to 78,150 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:38 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. bought $64,240 worth of shares (11,000 units at $5.84), increasing direct ownership by 10% to 124,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    11/6/25 8:00:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGH
    $BATL
    $CYRN
    $EDIT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ANGH
    $BATL
    $CYRN
    $EDIT
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Society Pass Incorporated

    S-1/A - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:26:07 PM ET
    $SOPA
    Real Estate

    Society Pass Incorporated filed SEC Form 8-K: Other Events

    8-K - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:00:27 PM ET
    $SOPA
    Real Estate

    Edgewell Personal Care Company filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - EDGEWELL PERSONAL CARE Co (0001096752) (Filer)

    2/6/26 4:11:03 PM ET
    $EPC
    Package Goods/Cosmetics
    Consumer Discretionary

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sainz Maria

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/6/26 9:21:10 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sainz Maria

    3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/6/26 9:18:07 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    EVP, CFO & Treasurer Macomber Lori sold $10,244 worth of shares (1,626 units at $6.30), decreasing direct ownership by 2% to 85,105 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    2/4/26 4:11:52 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Graham downgraded by Northland Capital with a new price target

    Northland Capital downgraded Graham from Outperform to Market Perform and set a new price target of $80.00

    1/27/26 8:29:26 AM ET
    $GHM
    Industrial Machinery/Components
    Industrials

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Graham Corporation Appoints Mauro Gregorio to Board of Directors

    Graham Corporation (NYSE:GHM) ("GHM" or "the Company"), a global leader in the design and manufacture of mission-critical fluid, power, heat transfer and vacuum technologies for the Defense, Energy & Process, and Space markets, today announced the appointment of Mauro Gregorio to its Board of Directors, effective September 1, 2025. Mr. Gregorio brings extensive global executive leadership experience and board governance expertise to Graham Corporation. He currently serves as a board member at Eagle Materials, and most recently served as a Board member of Radius Recycling and was President of the Performance Materials & Coatings division at Dow Inc., where he oversaw a $10 billion business

    9/3/25 8:00:00 AM ET
    $GHM
    Industrial Machinery/Components
    Industrials

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Financials

    Live finance-specific insights

    View All

    Graham Corporation Reports Third Quarter Fiscal 2026 Results

    Third Quarter Fiscal 2026 Highlights: Revenue increased 21% to $56.7 million Gross profit increased 15% to $13.5 million; Gross profit margin was 23.8% Net income per diluted share increased 79% to $0.25; adjusted net income per diluted share1 increased 72% to $0.31 Adjusted EBITDA1 increased 50% to $6.0 million; Adjusted EBITDA margin1 was 10.7% Orders2 were $71.7 million; Book-to-Bill ratio2 of 1.3x and record backlog2 of $515.6 million Strong balance sheet with no debt, $22.3 million in cash, and access to $43.0 million under its revolving credit facility at quarter end to support growth initiatives Updating and increasing full year fiscal 2026 guidance; Remain on tr

    2/6/26 6:30:00 AM ET
    $GHM
    Industrial Machinery/Components
    Industrials

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results

    Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Revenue of $537.1 million Net income of $69.3 million Adjusted EBITDA* of $84.7 million Fiscal Year 2026 Guidance Ranges: Revenue expected in a range of $1.61 billion to $1.71 billion Adjusted EBITDA* expected in a range of $90 million to $100 million Second Quarter Fiscal Year 2026 – Segment Highlights Senior Revenue of $261.5 million Adjusted EBITDA of $102.5 million Approved Medicare Advantage policies of 257,279 Healthcare Services Revenue of $230.7 million Adjusted EBITDA of $0.8 million 113,483 SelectRx members Life Revenue of $43.6 million Adjusted EBITDA of $5.6

    2/5/26 7:00:00 AM ET
    $SLQT
    Specialty Insurers
    Finance

    $ANGH
    $BATL
    $CYRN
    $EDIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by SES AI Corporation

    SC 13D/A - SES AI Corp (0001819142) (Subject)

    11/19/24 4:15:56 PM ET
    $SES
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Anghami Inc.

    SC 13D/A - Anghami Inc (0001871983) (Subject)

    11/19/24 4:15:31 PM ET
    $ANGH
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Leafly Holdings Inc.

    SC 13G/A - Leafly Holdings, Inc. /DE (0001785592) (Subject)

    11/14/24 5:35:46 PM ET
    $LFLY
    Computer Software: Prepackaged Software
    Technology